"10.1371_journal.pone.0036286","plos one","2012-04-30T00:00:00Z","Attila V√©gh; Anita Farkas; Dorottya K√∂vesdi; Kriszti√°n Papp; Judit Cervenak; Zita Schneider; Bal√°zs Bender; L√°szl√≥ Hiripi; Gl√≥ria L√°szl√≥; J√≥zsef Prechl; J√°nos Matk√≥; Imre Kacskovics","ImmunoGenes Kft, Budakeszi, Hungary; Department of Immunology, E√∂tv√∂s Lor√°nd University, Budapest, Hungary; Immunology Research Group, Hungarian Academy of Sciences, E√∂tv√∂s Lor√°nd University, Budapest, Hungary; Agricultural Biotechnology Center, G√∂d√∂ll≈, Hungary","Conceived and designed the experiments: LH JP JM IK. Performed the experiments: AV AF JC ZS BB. Analyzed the data: DK KP JC GL BB LH. Wrote the paper: IK.","The authors have read the journals policy and have the following conflicts: Dr. V√©gh, Dr. Cervenak and Dr. Bender are scientific researchers; Imre Kacskovics is co-founder and CEO of ImmunoGenes Ltd., Budakeszi, Hungary a company specialized in the generation of FcRn transgenic animals for the production of polyclonal and monoclonal antibodies (these animals are in development phase) (www.immunogenes.com). E√∂tv√∂s Lor√°nd University, Budapest, Hungary and Agriculture Biotechnology Center, G√∂d√∂ll≈, Hungary have been granted a European patent for this technology (Method using a transgenic animal with enhanced immune response; EP2097444), and seek patent in other major markets. The technology has been licensed exclusively to ImmunoGenes Ltd. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","04","Attila V√©gh","AV√",12,TRUE,4,5,6,1,TRUE,FALSE,FALSE,0,NA,FALSE
